Winfield Associates Inc. increased its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 6.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,822 shares of the biotechnology company’s stock after buying an additional 162 shares during the period. Winfield Associates Inc.’s holdings in bluebird bio were worth $296,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in BLUE. Arthur M. Cohen & Associates LLC bought a new stake in shares of bluebird bio during the second quarter valued at about $338,000. Strs Ohio increased its position in shares of bluebird bio by 25.4% in the second quarter. Strs Ohio now owns 7,400 shares of the biotechnology company’s stock worth $777,000 after buying an additional 1,500 shares during the period. Affinity Investment Advisors LLC acquired a new position in shares of bluebird bio during the second quarter worth about $246,000. Parametrica Management Ltd acquired a new position in shares of bluebird bio during the second quarter worth about $655,000. Finally, Russell Investments Group Ltd. increased its position in shares of bluebird bio by 15.0% in the second quarter. Russell Investments Group Ltd. now owns 38,882 shares of the biotechnology company’s stock worth $4,084,000 after buying an additional 5,059 shares during the period.
bluebird bio, Inc. (BLUE) traded up 4.33% during trading on Friday, reaching $93.95. The company had a trading volume of 553,360 shares. The firm’s 50 day moving average is $98.52 and its 200 day moving average is $90.12. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $123.75. The company’s market capitalization is $4.28 billion.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. The business had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company’s quarterly revenue was up 977.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.59) EPS. On average, equities research analysts predict that bluebird bio, Inc. will post ($6.78) earnings per share for the current year.
A number of research analysts have issued reports on the company. BidaskClub upgraded bluebird bio from a “sell” rating to a “hold” rating in a research note on Wednesday. BMO Capital Markets reiterated a “buy” rating and set a $108.00 price target on shares of bluebird bio in a research note on Friday, August 4th. Morgan Stanley reiterated a “hold” rating on shares of bluebird bio in a research note on Wednesday. Jefferies Group LLC reiterated a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research note on Friday. Finally, Cantor Fitzgerald set a $39.00 price target on bluebird bio and gave the stock a “sell” rating in a research note on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. bluebird bio has a consensus rating of “Hold” and an average target price of $100.66.
In related news, Director Daniel Lynch sold 2,500 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $120.03, for a total value of $300,075.00. Following the transaction, the director now owns 5,300 shares of the company’s stock, valued at $636,159. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Philip D. Gregory sold 750 shares of the stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $99.00, for a total value of $74,250.00. Following the completion of the transaction, the insider now directly owns 31,234 shares in the company, valued at approximately $3,092,166. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 77,856 shares of company stock worth $8,093,145. Insiders own 3.90% of the company’s stock.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.